TY - JOUR T1 - Correspondence on 'Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation’ by Braaten <em>et al</em> JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e13 LP - e13 DO - 10.1136/annrheumdis-2019-216867 VL - 81 IS - 1 AU - Fulvia Ceccarelli AU - Andrea Botticelli AU - Alain Jonathan Gelibter AU - Ilaria Leccese AU - Ramona Lucchetti AU - Enrico Cortesi AU - Guido Valesini AU - Paolo Marchetti AU - Fabrizio Conti Y1 - 2022/01/01 UR - http://ard.bmj.com/content/81/1/e13.abstract N2 - We read with interest the study published by Braaten and colleagues, analysing the long-term outcomes of 60 patients developing persistent inflammatory arthritis (IA) after immune checkpoint inhibitors (ICIs) cessation. The most relevant result of the study was the presence of active arthritis in more than half of the patients at the last follow-up visit.1 We report here our experience in the context of a joint oncology/rheumatology outpatient clinic, in order to evaluate the risk of developing IA in patients treated by anti-PD1 drugs. During 1-year period, we consecutively assessed all the adult patients candidate to anti-PD1 treatment, referring to the Oncology Unit at the Sapienza University of Rome. After treatment starts, in the case of musculoskeletal manifestations, patients were referred to the Sapienza Arthritis Center, Rheumatology Unit, Sapienza University of Rome. Arthritis was defined as the occurrence of at least one episode of clinical synovitis, with morning stiffness lasting at least 30 min. … ER -